{'fraction_non_alphanumeric': 0.030456852791878174, 'fraction_numerical': 0.01353637901861252, 'mean_word_length': 5.166666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Precision monitoring takes the stage.

In this issue of Blood, Assouline et al report the clinical activity of the oral histone deacetylase inhibitor, panobinostat, in 40 patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not preselected on the basis of molecular subtype as well as transformed lymphomas.1 The authors found a modest overall response rate (ORR) of 28% in the entire cohort with no benefit from the addition of rituximab. Importantly, a subset of responders achieved relatively durable remissions, including 6 responders (55%) who had yet to progress.